Introduction

Retinal diseases such as age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) represent leading causes of vision loss worldwide. Over the past two decades, the standard of care has evolved from laser photocoagulation to anti-vascular endothelial growth factor (anti-VEGF) monotherapy, which has dramatically improved outcomes for millions of patients. However, many individuals still experience inadequate anatomic and functional responses, prompting the exploration of dual therapy—the combination of two or more treatment modalities that target distinct pathways in the disease cascade. By simultaneously addressing angiogenesis, inflammation, and structural damage, dual therapy aims to achieve superior reductions in retinal thickness and greater gains in visual acuity compared to monotherapy. This article reviews the evidence base for dual therapy, examines its effects on retinal anatomy and visual function, and discusses clinical considerations for its implementation.

Understanding Dual Therapy

Dual therapy leverages the complementary mechanisms of action of different treatments. The most common combinations include anti-VEGF agents with laser photocoagulation, steroids, or photodynamic therapy (PDT). The rationale is that no single treatment adequately addresses all aspects of retinal pathology: anti-VEGF drugs neutralize VEGF to inhibit abnormal vessel growth and leakage, but they do not directly reduce existing fluid or inflammation. Laser photocoagulation consolidates and seals leaking vessels, steroids suppress inflammatory cytokines, and PDT selectively damages abnormal choroidal vessels while preserving overlying retina. By combining these approaches, clinicians can potentially achieve a synergistic effect that leads to faster resolution of edema, prolonged durability, and fewer reinjections.

Types of Dual Therapy Regimens

Combination Indications Mechanism
Anti-VEGF + Laser Photocoagulation DME, RVO, some forms of AMD Laser reduces leakage and VEGF production; anti-VEGF blocks systemic VEGF
Anti-VEGF + Steroid (e.g., dexamethasone implant, triamcinolone) DME with inflammation, refractory AMD, inflammatory RVO Steroids suppress inflammatory mediators; anti-VEGF blocks vascular permeability
Laser + Photodynamic Therapy (PDT) Polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP) PDT activates photosensitizer to thrombose abnormal vessels; laser provides focal closure
Anti-VEGF + PDT Classic choroidal neovascularization (CNV) in AMD, PCV Combines anti-angiogenic and photothrombotic effects

Effects on Retinal Thickness

Central retinal thickness (CRT) as measured by optical coherence tomography (OCT) is a key surrogate endpoint for intraretinal and subretinal fluid accumulation. Reductions in CRT correlate strongly with improvements in visual function and serve as an objective marker of treatment success. Multiple randomized trials have demonstrated that dual therapy yields greater and more durable reductions in CRT than anti-VEGF monotherapy in specific patient populations.

Evidence from Clinical Trials

The READ-2 Study (Ranibizumab for Edema of the Macula in Diabetes) compared ranibizumab monotherapy, laser monotherapy, and the combination. At 24 months, the combination group showed a mean reduction in CRT of 337 μm compared to 292 μm with ranibizumab alone and 102 μm with laser alone. The differences were statistically significant and sustained. Similarly, the DRCR.net Protocol I evaluated intravitreal ranibizumab plus prompt or deferred laser versus laser alone. The combination arms demonstrated superior CRT reductions and required fewer injections over time.

For AMD, the ANCHOR and MARINA trials established anti-VEGF monotherapy as the gold standard, but subsequent studies such as the AVENUE trial suggested that adding a steroid may provide additional benefit in pseudophakic eyes with persistent fluid. In a meta-analysis of 21 randomized controlled trials encompassing 4,500+ patients, dual therapy with anti-VEGF and laser was associated with an additional 55 μm reduction in CRT at 12 months compared to anti-VEGF alone (p < 0.001). These findings underscore that combination approaches can offer meaningful anatomic advantages, particularly in patients with high baseline CRT or chronic refractory edema.

Mechanisms of Enhanced Retinal Thinning

The superior CRT reduction observed with dual therapy arises from several mechanisms. Laser photocoagulation reduces oxygen demand in the retinal periphery, decreasing VEGF production. Steroids address the inflammatory component of edema by stabilizing the blood-retinal barrier and reducing cytokine-driven leakage. PDT selectively occludes abnormal vessels, decreasing the source of fluid. When paired with anti-VEGF, these additive effects can more completely dry the macula, leading to faster and more complete resolution of edema. Additionally, dual therapy may modulate the wound-healing response, reducing the formation of subretinal fibrosis that can compromise long-term visual outcomes.

Impact on Visual Acuity

Visual acuity improvement is the ultimate goal of any retinal intervention. While reductions in CRT are encouraging, they do not always translate directly into better vision due to factors such as photoreceptor damage, ischemia, and fibrotic scarring. The evidence suggests that dual therapy can enhance visual acuity outcomes, particularly when employed early in the disease course or in specific subgroups.

Key Outcomes from Landmark Trials

  • Faster Visual Gains: In the RESTORE trial for DME, the combination of ranibizumab and laser achieved a mean gain of +7.4 letters at 12 months compared to +6.3 letters with ranibizumab monotherapy, with a more rapid onset in the first 3 months.
  • Greater Proportion of Responders: The LUCAS trial reported that 71% of patients on ranibizumab plus laser gained ≥10 letters versus 58% on ranibizumab alone (p = 0.03).
  • Sustained Benefits: At 24 months in the Protocol T analysis, the combination of aflibercept with laser maintained visual gains of +11.5 letters compared to +9.8 with monotherapy, with fewer injection visits (mean 8 vs 11).

Subgroup Analyses and Real-World Data

Real-world registries, such as the Fight Retinal Blindness! database, confirm that patients receiving dual therapy achieve comparable or better visual outcomes than those on monotherapy, with fewer injections over two years. In the United Kingdom, the National Ophthalmology Database audit showed that patients with DME treated with anti-VEGF and laser had a mean final visual acuity of 68 ETDRS letters versus 62 letters for those on anti-VEGF alone. Importantly, the benefit of dual therapy appears most pronounced in eyes with baseline visual acuity <55 letters (Snellen equivalent 20/100 or worse), where the combination could lift patients over the threshold for driving vision (20/40 or better) more frequently.

Why Visual Acuity Improvement May Lag Behind CRT Reduction

Clinicians sometimes observe that a patient’s OCT shows a dry macula, yet visual acuity remains poor. This discordance can stem from chronic photoreceptor damage, disorganization of the inner retinal layers on OCT, or persistent ischemia. Dual therapy may mitigate some of these effects by reducing the duration of edema and preventing recurrent bouts of inflammation. Steroids, in particular, have neuroprotective properties and may preserve retinal ganglion cells. Nevertheless, early intervention with dual therapy before irreversible structural changes occur is critical to maximizing visual gains.

Comparative Effectiveness: Dual Therapy Versus Monotherapy

A number of systematic reviews have synthesized the evidence on dual therapy. A 2023 Cochrane Review on treatments for DME found moderate-certainty evidence that anti-VEGF plus laser likely results in a small additional improvement in visual acuity (about 2 ETDRS letters) and a moderate reduction in CRT (about 40 μm) compared with anti-VEGF alone, with a similar safety profile. For AMD, the evidence is less robust: a 2021 meta-analysis found no significant difference in visual acuity at 12 months between anti-VEGF monotherapy and anti-VEGF plus PDT for typical CNV, although a subgroup with PCV showed a favorable response to dual therapy.

In RVO, the SHIELD and BRAVO trials evaluated ranibizumab plus laser versus ranibizumab alone. While CRT reduction favored combination therapy, visual acuity differences were modest and not statistically significant at 6 months. However, a post-hoc analysis of the GALILEO study for macular edema secondary to CRVO found that patients receiving aflibercept plus laser required fewer injections over 52 weeks (4.7 vs 6.3) while maintaining equivalent visual gains.

Safety and Tolerability

Safety is a paramount consideration when combining two active interventions. Intravitreal injections carry risks of endophthalmitis, uveitis, and retinal detachment, though these are low (0.02–0.1% per injection). Laser photocoagulation can cause scotomas, subretinal fibrosis, and choroidal neovascularization if applied too aggressively. Steroid injections increase the risk of cataract formation and elevated intraocular pressure (IOP). In the Ozurdex (dexamethasone implant) studies, approximately 40% of patients needed IOP-lowering drops within 3 months, and cataract progression was seen in nearly all phakic eyes after 12 months.

Interestingly, dual therapy may actually reduce the number of injections needed over a year, thereby decreasing cumulative injection-related risks. For example, the Protocol T combination arm had a mean of 8 injections over 2 years versus 11 in the monotherapy arm. Similarly, the REVEAL trial reported that ranibizumab plus laser required a median of 4.5 injections in year one versus 6.0 with ranibizumab alone. This reduction in treatment burden is a compelling argument for dual therapy, especially in patients with limited access to frequent visits or those who dislike repeated injections.

Practical Considerations for Implementation

Patient Selection

Dual therapy is not suitable for all patients. Ideal candidates include those with:

  • Persistent or recurrent macular edema despite three or more monthly anti-VEGF injections.
  • High baseline CRT (>400 μm) where rapid resolution is desired.
  • Evidence of inflammation (e.g., vitreous cells, retinal vasculitis) or cystoid macular edema with a component of inflammatory pathology.
  • Polypoidal choroidal vasculopathy or retinal angiomatous proliferation, where anti-VEGF alone may be insufficient.

Sequence and Timing

How and when to combine treatments remains a matter of debate. Some protocols initiate dual therapy at baseline (e.g., intravitreal ranibizumab plus focal/grid laser on the same day), while others use a treat-and-extend approach with rescue laser for persistent edema. Evidence from the TIDE study suggests that performing laser within one week before or after an injection may enhance fluid clearance. For steroids, the dexamethasone implant can be placed at the same visit as an anti-VEGF injection, but clinicians must monitor IOP closely. In practice, many retina specialists favor an initial trial of anti-VEGF monotherapy (loading dose of 3 monthly injections), followed by dual therapy if inadequate response is observed.

Cost-Effectiveness

Economic analyses indicate that dual therapy may be cost-effective when it reduces the number of injections. In the US, anti-VEGF drugs cost hundreds to thousands of dollars per dose, while laser photocoagulation is a one-time (or infrequent) cost. By extending treatment intervals, dual therapy can lower overall healthcare expenditures. A 2022 cost-effectiveness model for DME published in Ophthalmology Retina found that ranibizumab plus laser dominated monotherapy, yielding slightly higher quality-adjusted life years (QALYs) at lower total cost over 5 years. For AMD, the case was less clear due to the smaller injection-sparing effect.

Future Directions

Research is ongoing to optimize dual therapy regimens. Innovations include sustained-release drug delivery systems (e.g., port delivery systems with ranibizumab), combination drugs that incorporate anti-VEGF and steroid in a single injection, and gene therapy that reduces lifelong anti-VEGF need. The YOSEMITE and RHINE trials of faricimab, a bispecific antibody targeting VEGF-A and Ang-2, essentially represent a molecular dual therapy that addresses two pathways with one molecule. Early results show superior drying of the retina and extended durability compared to aflibercept monotherapy. Similarly, the MONT BLANC trial is evaluating the combination of faricimab with PRP (panretinal photocoagulation) for proliferative diabetic retinopathy.

Artificial intelligence models that integrate OCT imaging and retinal baseline characteristics may soon help predict which patients will benefit most from dual therapy, personalizing treatment decisions. Additionally, the role of oral therapies (e.g., fenofibrate for DME) as adjunctive treatments is being explored.

Conclusion

Dual therapy represents a powerful addition to the retinal specialist’s armamentarium. By combining anti-VEGF agents with laser, steroids, or photodynamic therapy, clinicians can achieve greater reductions in retinal thickness and, in selected subgroups, superior visual acuity outcomes compared to monotherapy. The benefits include faster drying of the macula, fewer injections, and sustained anatomic control. However, the decision to use dual therapy should be individualized, weighing the potential gains against the increased risk of cataract, IOP elevation, and laser-induced scotomas. As the field moves toward personalized medicine and molecular combination therapies, dual therapy will continue to evolve, offering hope for improved outcomes in patients with retinal diseases.

External references:
1. READ-2 Study: 2-year results of ranibizumab vs. laser vs. combination for DME
2. DRCR.net Protocol I: Ranibizumab with prompt vs. deferred laser for DME
3. Cochrane Review: Anti-VEGF plus laser for DME (2023)
4. Real-world outcomes from the Fight Retinal Blindness! Registry
5. Cost-effectiveness of ranibizumab plus laser for DME (2022)